Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 4:12:749047.
doi: 10.3389/fneur.2021.749047. eCollection 2021.

Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases

Paul S Fishman  1 , Jonathan M Fischell  1
Affiliations
Review

Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases

Paul S Fishman et al. Front Neurol. .

Abstract

The blood brain barrier (BBB) is an obstacle for the delivery of potential molecular therapies for neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). Although there has been a proliferation of potential disease modifying therapies for these progressive conditions, strategies to deliver these large agents remain limited. High intensity MRI guided focused ultrasound has already been FDA approved to lesion brain targets to treat movement disorders, while lower intensity pulsed ultrasound coupled with microbubbles commonly used as contrast agents can create transient safe opening of the BBB. Pre-clinical studies have successfully delivered growth factors, antibodies, genes, viral vectors, and nanoparticles in rodent models of AD and PD. Recent small clinical trials support the safety and feasibility of this strategy in these vulnerable patients. Further study is needed to establish safety as MRI guided BBB opening is used to enhance the delivery of newly developed molecular therapies.

Keywords: Alzheimer's disease; FUS; Parkinson's disease; blood-brain barrier; focused ultrasound (MRgFUS).

PubMed Disclaimer

Conflict of interest statement

PF has received funding from Insightec which has funded some of the clinical studies cited. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling Editor declared a past co-authorship with one of the authors, PF.

References

    1. de la Torre JC, Gonzalez-Lima F. The FDA approves aducanumab for Alzheimer's disease, raising important scientific questions. J Alzheimers Dis. (2021) 2021:210736. 10.3233/JAD-210736 - DOI - PubMed
    1. Kimura S, Harashima H. Current status and challenges associated with CNS-targeted gene delivery across the BBB. Pharmaceutics. (2020) 12:1216. 10.3390/pharmaceutics12121216 - DOI - PMC - PubMed
    1. Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH. Human gene therapy approaches for the treatment of Parkinson's disease: an overview of current andcompleted clinical trials. Parkinsonism Relat Disord. (2019) 66:16–24. 10.1016/j.parkreldis.2019.07.018 - DOI - PubMed
    1. Olanow CW, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al. . Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol. (2015) 78:248–57. 10.1002/ana.24436 - DOI - PubMed
    1. Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. (2012) 503:269–92. 10.1016/B978-0-12-396962-0.00011-2 - DOI - PubMed